DysRegNet: Patient-specific and confounder-aware dysregulated network inference towards precision therapeutics.
3/5 보강
TL;DR
A user‐friendly implementation for the analysis and interpretation of patient‐specific gene‐regulatory networks is missing and does not account for clinically important confounding factors such as age, sex or treatment history.
연도별 인용 (2025–2026) · 합계 2
OpenAlex 토픽 ·
Bioinformatics and Genomic Networks
Genetic Associations and Epidemiology
Advanced Graph Neural Networks
A user‐friendly implementation for the analysis and interpretation of patient‐specific gene‐regulatory networks is missing and does not account for clinically important confounding factors such as age
APA
Johannes Kersting, Olga Lazareva, et al. (2026). DysRegNet: Patient-specific and confounder-aware dysregulated network inference towards precision therapeutics.. British journal of pharmacology, 183(8), 1709-1724. https://doi.org/10.1111/bph.17395
MLA
Johannes Kersting, et al.. "DysRegNet: Patient-specific and confounder-aware dysregulated network inference towards precision therapeutics.." British journal of pharmacology, vol. 183, no. 8, 2026, pp. 1709-1724.
PMID
39631757 ↗
Abstract 한글 요약
[BACKGROUND AND PURPOSE] Gene regulation is frequently altered in diseases in unique and patient-specific ways. Hence, personalised strategies have been proposed to infer patient-specific gene-regulatory networks. However, existing methods do not scale well because they often require recomputing the entire network per sample. Moreover, they do not account for clinically important confounding factors such as age, sex or treatment history. Finally, a user-friendly implementation for the analysis and interpretation of such networks is missing.
[EXPERIMENTAL APPROACH] We present DysRegNet, a method for inferring patient-specific regulatory alterations (dysregulations) from bulk gene expression profiles. We compared DysRegNet to the well-known SSN method, considering patient clustering, promoter methylation, mutations and cancer-stage data.
[KEY RESULTS] We demonstrate that both SSN and DysRegNet produce interpretable and biologically meaningful networks across various cancer types. In contrast to SSN, DysRegNet can scale to arbitrary sample numbers and highlights the importance of confounders in network inference, revealing an age-specific bias in gene regulation in breast cancer. DysRegNet is available as a Python package (https://github.com/biomedbigdata/DysRegNet_package), and analysis results for 11 TCGA cancer types are available through an interactive web interface (https://exbio.wzw.tum.de/dysregnet).
[CONCLUSION AND IMPLICATIONS] DysRegNet introduces a novel bioinformatics tool enabling confounder-aware and patient-specific network analysis to unravel regulatory alteration in complex diseases.
[LINKED ARTICLES] This article is part of a themed issue Network Medicine and Systems Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.8/issuetoc.
[EXPERIMENTAL APPROACH] We present DysRegNet, a method for inferring patient-specific regulatory alterations (dysregulations) from bulk gene expression profiles. We compared DysRegNet to the well-known SSN method, considering patient clustering, promoter methylation, mutations and cancer-stage data.
[KEY RESULTS] We demonstrate that both SSN and DysRegNet produce interpretable and biologically meaningful networks across various cancer types. In contrast to SSN, DysRegNet can scale to arbitrary sample numbers and highlights the importance of confounders in network inference, revealing an age-specific bias in gene regulation in breast cancer. DysRegNet is available as a Python package (https://github.com/biomedbigdata/DysRegNet_package), and analysis results for 11 TCGA cancer types are available through an interactive web interface (https://exbio.wzw.tum.de/dysregnet).
[CONCLUSION AND IMPLICATIONS] DysRegNet introduces a novel bioinformatics tool enabling confounder-aware and patient-specific network analysis to unravel regulatory alteration in complex diseases.
[LINKED ARTICLES] This article is part of a themed issue Network Medicine and Systems Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.8/issuetoc.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.